[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-cardiac-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-cardiac-surgery":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,75,98,131,161,194],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100635707","medlypeds-feasibility-study-100635707",false,"NCT07556185","MedlyPeds Feasibility Study","MedlyPeds Feasibility Study: A Mobile, Smartdevice Based Telemonitoring for Pediatric Heart Disease, a Prospective Cohort Study","Inclusion Criteria:\n\n1. Consent provided.\n2. Aged 8-18 years of age.\n3. Ability to comply with using Medly (ex. able to stand on the weight scale, able to answer symptom questions, etc.)\n4. Followed at the Hospital for Sick Children Cardiology Clinic for any of the following reasons:\n\n   1. Heart failure of any etiology\n   2. Congenital heart disease\n   3. Acquired heart disease (eg. Kawasaki disease, rheumatic heart disease, connective tissue disorders etc)\n   4. Pulmonary hypertension\n   5. Post-cardiac surgery including heart transplant and ventricular assist devices\n\nExclusion Criteria:\n\n1. Unable to read or write in English.\n2. Participating in another clinical trial that may confound the results.\\* \\*Participant may be re-screened for eligibility at a later date.","ALL","8 Years","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","SickKids and UHN have developed MedlyPeds which is a smart phone application designed to remotely monitor patients with heart disease. This is a feasibility study which will enroll up to 30 patients with different types of heart disease to see which patient types may benefit the most from MedlyPeds if it were to be used for clinical monitoring. The study is gathering feedback about the app from patients, parents and clinicians to confirm how it needs to be modified to better serve the purpose in a future trial.",[27,28,29,30,31],"Pediatric Heart Failure","Congenital Heart Disease (CHD)","Acquired Heart Disease","Pulmonary Hypertension","Post Cardiac Surgery",[33,34],"Medly","Telemonitoring","RECRUITING","2026-06-23",{"date":38,"type":39},"2026-06-26","ACTUAL",{"date":41,"type":21},"2026-07",{"date":43,"type":21},"2029-12",{"name":45,"class":46},"The Hospital for Sick Children","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100419996","phase-3-vernakalant-versus-amiodarone-for-post-operative-atrial-fibrillation-in-cardiac-surgery-patients-100419996","NCT04748991","Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients","Inclusion Criteria:\n\n1. Age \\>\u002F=18 years\n2. Undergone heart surgery for coronary artery bypass surgery (on-pump or off-pump CABG) and\u002For valve repair or replacement (excluding mechanical valves), including re-operations.\n3. Hemodynamically stable with\u002Fwithout vasopressor support\n\nExclusion Criteria:\n\n1. LVAD insertion or heart transplantation\n2. MAZE procedure\n3. Transcatheter aortic valve replacement (TAVR)\n4. History of or planned mechanical valve replacement\n5. Rheumatic heart disease\n6. Congenital cardiac defect (excluding bicuspid aortic valve or patent foramen ovale)\n7. History of prior atrial fibrillation or flutter\n8. History of ablation for atrial fibrillation\n9. Contraindication to amiodarone\n\n   * PR \\>240ms\n   * Heart block (2nd or 3rd degree)\n   * QTC \\>480ms\n   * Untreated thyroid disorder\n   * AST or ALT \\>2x upper limit of normal\n   * Hepatic cirrhosis\n   * Interstitial lung disease\n10. Received amiodarone within 6 weeks\n11. Contraindications to Vernakalant\n\n    * Known hypersensitivity to Vernakalant\n    * Prolonged QT\n    * Heart block (2nd or 3rd degree)\n    * Use of anti-arrhythmic medication in the past 4 weeks.\n12. Return to OR during CVICU stay or readmission to CIVCU from Cardiac Surgery ward.",{"count":55,"type":21},50,[57],"PHASE3","Post-operative atrial fibrillation is a common problem post cardiac surgery with rates exceeding 30%. Atrial fibrillation has multiple adverse effects on cardiac hemodynamics and can lead to hypotension, diminished end organ perfusion and lengthen the stay in ICU. Amiodarone is the medication of choice used for pharmacological cardioversion and can be used with vasoactive medications. Intravenous amiodarone is associated with hypotension and end organ perfusion requiring escalation in vasoactive support. Vernakalant is novel anti-arrhythmic agent approved in Canada for cardioversion of atrial fibrillation that primarily works on atrial channels and has no effect on contractility or vasodilation. Clinical trials have proved good efficacy of Vernakalant in conversion of paroxysmal atrial fibrillation however there is no comparison of Amiodarone to Vernakalant in post-operative cardiac surgery. We plan to perform a clinical trial comparing Vernakalant to amiodarone in post-cardiac surgery patients with a primary outcome of cardioversion at 90 minutes. Secondary outcomes will follow duration of vasoactive medications, days in ICU and economics.",[60,61],"Atrial Fibrillation","Post-cardiac Surgery",[63,64],"Amiodarone","Vernakalant","NOT_YET_RECRUITING","2026-06-01",{"date":68,"type":39},"2026-06-03",{"date":70,"type":21},"2026-09",{"date":72,"type":21},"2029-09",{"name":74,"class":46},"University of Calgary",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":47},"100563863","effect-of-neuromuscular-electrical-stimulation-on-phrenic-nerve-regeneration-post-cardiac-surgeries-100563863","NCT06621693","Effect of Neuromuscular Electrical Stimulation on Phrenic Nerve Regeneration Post Cardiac Surgeries","Inclusion Criteria:\n\n* Patients post cardiac surgery (coronary artery bypass graft, valve repair or replacement ).\n* Patients referred by physician.\n* Medically stable patients.\n* Both genders\n* Ages from 25 to 45\n* BMI 25-29.9 kg\u002Fm2\n* Able to understand the requirements of the study.\n* Conscious patient and respond to verbal commands.\n\nExclusion Criteria:\n\nParticipants will be excluded if they meet one of the following criteria:\n\n* Patients with rib fracture.\n* Patients developing lung cancer.\n* Patients have dementia.\n* Patients on mechanical ventilator after 24 hours\n* Metabolically unstable chronic illness",true,"25 Years","45 Years",{"count":85,"type":21},60,[24],"This study will be conducted to investigate the effect of neuromuscular electrical stimulation on phrenic regeneration post cardiac surgery",[61],"2024-09-29",{"date":91,"type":39},"2024-10-01",{"date":93,"type":21},"2024-10-04",{"date":95,"type":21},"2025-01-30",{"name":97,"class":46},"Cairo University",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100563208","phase-4-intravenous-acetaminophen-after-cardiac-surgery---definitive-study-100563208","NCT06613178","Intravenous Acetaminophen After Cardiac Surgery - Definitive Study","Intravenous Acetaminophen After Cardiac Surgery","IVACS","Inclusion Criteria:\n\ngreater or equal to 18\n\n* elective cardiac surgery\n* stable pre-operative\n* aorto-coronary bypass with or without 1 valve replacement.\n\nExclusion Criteria:\n\nRefusal by surgeon Requested late extubation by surgeon or anesthesia Intra-aortic balloon pump Mechanical cardiac support Sensitivity to acetaminophen Psychiatric history with current active treatment Alzheimer\\'s disease Seizure in previous 6 months Recent history of alcohol misuse Cognitive impairment\n\n\\-",{"count":107,"type":21},1100,[109],"PHASE4","Double blind, double dummy trial of the use of IV acetaminophen versus oral acetaminophen for the prevention of delirium after cardiac surgery. The underlying hypothesis is that better pain control and less use of narcotics will lead to a lower incidence of delirium from day 1 to 7 following cardiac surgery. Other important secondary outcomes are the total use of narcotics, ICU and hospital stay, improved cognitive function at 6 months and 1 year post surgery, NSAID use at each centre and associated NSAID complications.",[112,113,114,61],"Post Operative Delirium","Post Operative Pain","Post-Op Complication",[116,117,118,119,120],"pain","post-operative care","cardiac surgery","narcotic","acetaminophen","2024-09-23",{"date":123,"type":39},"2024-09-25",{"date":125,"type":39},"2024-07-02",{"date":127,"type":21},"2027-12-15",{"name":129,"class":46},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",8,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":47},"100551488","comb-effect-of-4-7-8-breathing-technique-and-stationary-cycle-on-pp-qol-and-dyspnea-in-post-cabg-patients-100551488","NCT06460740","Comb Effect of 4-7-8 Breathing Technique and Stationary Cycle on PP, QOL and Dyspnea in Post CABG Patients.","Combined Effects of 4-7-8 Breathing Technique and Stationary Cycle on Physical Performance, Quality of Life and Dyspnea in Post CABG Patients","Inclusion Criteria:\n\n* Patients who underwent a successful CABG (no complications during surgery\n* and\u002For in the following weeks)\n* Female and male whose age between 40 to 70 years of age\n* Phase II cardiac rehab patients\n* Patients who were extubated and hemodynamically stable\n* Patients with stable chronic heart failure.\n* Patients had no arrhythmias\n* Patients who had ability to read and write\n* Patients who voluntarily participated in the study.\n\nExclusion Criteria:\n\n* Ventricular Septal defect repair.\n* Patients have limitation of motion that prevents them from performing physical activities such as walking for 6 minute.\n* Patients who had undergone previous cardiac surgery.\n* Severe renal dysfunction requiring dialysis.\n* Altered level of consciousness.\n* A history of musculoskeletal problems\n* Having an orthopedic problem that prevents the use of lower and upper extremity bikes.\n* Cancer patients receiving radiotherapy and chemotherapy.\n* Clinical diagnosis of uncontrolled Diabetes Mellitus and Hypertension.\n* Physical Discomfort at any stage of the study and\u002For any reaction to the tests (nausea, dizziness, discomfort, feeling faint, tachycardia, excessive sweating), and if they failed to attend the scheduled sessions.","40 Years","70 Years",{"count":141,"type":21},58,[24],"To determine the combined effects of 4-7-8 breathing technique and stationary cycle on physical performance, quality of life and dyspnea in post CABG patients.",[61],[146,147,148,149,150,151],"4-7-8 breathing technique","stationary cycling","Post CABG","physical performance","quality of life","Dyspnea","2024-06-24",{"date":154,"type":39},"2024-06-26",{"date":156,"type":39},"2024-01-01",{"date":158,"type":21},"2024-07-01",{"name":160,"class":46},"Riphah International University",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":178,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":193},"100542090","pharmacokinetics-and-modelling-of-beta-lactam-in-ecmo-va-patients-100542090","NCT06338345","Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients","Pharmacokinetics and Modelling of Beta-Lactam in Patients Undergoing Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO)","KAMELOT","Inclusion Criteria:\n\n* Patients undergoing VA-ECMO\n* Patients requiering initiation of a novel antibiotic therapy with one of the studied beta-lactam (Piperacillin-Tazobactam, Cefepime, or Meropenem) while under VA-ECMO\n* With an expected survival exceeding 24 hours\n* Patient's or their trusted person's consent\n\nExclusion Criteria:\n\n* Subject under administrative or judicial surveillance\n* Non-affiliation to social insurance\n* Pregnant or lactating patient\n* Antibiotic therapy of interest already initiated before VA-ECMO implantation\n* Contraindication to the use of beta-lactam\n* Administration modalities of beta-lactam not compliant with current recommendations\n* Subject in exclusion period from another study",{"count":170,"type":21},225,[24],"The use of antibiotic therapy is common in intensive care units and primarily involves beta-lactams. Its optimal implementation is made difficult by the pharmacokinetic changes inherent in critically ill patients.\n\nDespite the current recommendations from the French Society of Anesthesiology and Intensive Care (SFAR) and the French Society of Pharmacology and Therapeutics (SFPT), there are no recommendations on prescription modalities for patients under veno-arterial extracorporeal membrane oxygenation (VA-ECMO). The use of antibiotic therapy is common in VA-ECMO patients and their pharmacokinetic variability factors are then exacerbated.\n\nWe aim to conduct a prospective, multicenter, interventional study designed to identify predictive factors for failure to achieve therapeutic target circulating concentrations of beta-lactams in patients under VA-ECMO treated with one of the studied beta-lactams",[174,61,175,176,177],"Cardiogenic Shock","Cardiac Arrest","Extracorporeal Membrane Oxygenation Complication","Infections",[179,180,181,182,183],"VA-ECMO","Infection","Beta-lactam","Pharmacokinetic","Modelling","2024-03-21",{"date":186,"type":39},"2024-03-29",{"date":188,"type":21},"2024-09-01",{"date":190,"type":21},"2028-09-01",{"name":192,"class":46},"University Hospital, Grenoble",5,{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":202,"enrollmentInfo":203,"targetDuration":205,"studyType":206,"phases":4,"briefSummary":207,"conditions":208,"keywords":211,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":47},"100387892","post-surgery-extracorporeal-life-support-100387892","NCT04330651","Post-Surgery Extracorporeal Life Support","Outcomes' Predictors in Post-Surgery Extracorporeal Life Support","PC-ECLS","Inclusion Criteria:\n\n* Patients underwent cardiac surgery\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years","80 Years",{"count":204,"type":21},500,"20 Years","OBSERVATIONAL","Extracorporeal Life Support (ECLS) may provide pulmonary and circulatory support for patients with acute heart failure refractory to conventional medical therapy. However, indications and effectiveness of ECLS engagement post-surgery remains a concern. The investigators sought to analyze indications, modality and outcomes of PS-ECLS, to identify predictors of early and midterm survival after PS-ECLS. The investigators have recorded prospectively, and analysed data of 209 consecutive PS-ECLS patients between January 2004 and December 2018. Demographic and clinical data before, during and after PS-ECLS were collected and their influence on hospital mortality and outcomes (early and midterm) will analyse. Multivariate analysis of pre PS-ECLS implantation factors (as age, female sex , insulin-dependent diabetes, pulmonary hypertension, STS, type of surgical procedure data, pre-ECLS blood lactate level) will be made for identify prognostic risk factors of in-hospital mortality. Overall survival will be analysed, at 6 months,1-year and 5-years, respectively and the factors influencing mild\u002Fterm outcome will be investigated.",[174,209,176,210,61],"Extracorporeal Life Support","Post Cardiac Arrest Syndrome",[212,213,214,215,216,217],"extracorporeal life support","ecls","ecmo","outocome","prognostic factors","extracorporeal membrane oxygenation","2021-04-27",{"date":220,"type":39},"2021-04-28",{"date":222,"type":4},"2004-01",{"date":224,"type":21},"2029-01-31",{"name":226,"class":46},"University of Florence"]